Intellia Therapeutics (NTLA) AI Stock Analysis

• Market Cap: $928.11M
• Dividend Yield: N/A
• Average Volume (3M): 4.98M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.47
• Revenue Growth: -13.37%
• EPS Growth: 2.57%
• Country: US
• Employees: 403
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -1.10
• Shares Outstanding: 103,583,400
• 10 Day Avg. Volume: 4,800,247
• 30 Day Avg. Volume: 4,977,385
• PEG Ratio: -4.30
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.25
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 4.42
• Enterprise Value/Gross Profit: 21.04
• Enterprise Value/Ebitda: -0.41
• 1Y Price Target: $29.65
• Price Target Upside: 208.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 22

• Rating: 50 Neutral
• Price Target: $8.50 ▼(-11.46%Downside)

Intellia's score is driven by its challenging financial performance and valuation metrics, partially offset by strong earnings call sentiment and technical indicators. The company's progress in clinical trials provides a positive outlook, but significant financial risks remain due to continued losses and negative cash flows.

Positive Factors

Clinical Trial Progress

The Phase 3 HAELO study has completed screening ahead of schedule, indicating strong progress in the program.

Safety Profile

The updated safety profile for lonvo-z was consistent with previous results, showing no serious adverse events and manageable infusion-related reactions.

Treatment Effectiveness

A single dose of lonvo-z led to a 98% mean reduction in the monthly HAE attack rate in all 10 patients.

Negative Factors

Clinical Uncertainty

The potential for a larger sample size in Phase II to lead to an inferior effect compared to Phase I results suggests uncertainty in replicating earlier success.

Market Opportunity

The HAE market and available treatments limit Lonvo-z opportunity size, suggesting limited uptake.

Valuation Concerns

The valuation disconnect between the HAE opportunity and NTLA’s market cap is one of the widest, which may persist until NTLA releases pivotal HAE data or addresses investor concerns on the balance sheet.

Intellia Therapeutics Business Overview & Revenue Model

Company Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Intellia Therapeutics generates revenue through a combination of collaborations, strategic partnerships, and the development of its proprietary gene-editing therapies. The company enters into agreements with other pharmaceutical companies and research institutions to co-develop and commercialize CRISPR-based therapies, which often involve upfront payments, milestone payments, and royalties on product sales. Additionally, Intellia invests in its pipeline of therapeutic candidates, driving long-term revenue potential through the successful development and eventual commercialization of these products. Strategic partnerships play a significant role in the company's earnings, providing both financial support and shared expertise to advance its gene-editing technology.

Intellia Therapeutics Financial Statement Overview

Summary

Intellia Therapeutics is experiencing typical financial challenges for a biotech company in a growth phase, with high R&D expenses leading to net losses and negative cash flows. Despite a strong cash position, the decline in revenue and shareholder equity indicates financial instability.

Income Statement

Intellia Therapeutics has faced a challenging financial environment, with declining revenues from $57.99 million in 2020 to $36.27 million in 2023, and ultimately to zero in 2024. The company has consistently incurred net losses, with a significant net loss of $519.02 million in 2024, indicating high operational costs and low revenue, characteristic of a biotech firm in early stages of development.

Balance Sheet

The balance sheet shows adequate cash reserves with $601.52 million in cash and equivalents. However, the debt-to-equity ratio stands at 0.24, indicating manageable leverage, but the persistent decrease in stockholders' equity from $1.05 billion in 2023 to $871.96 million in 2024 suggests a deterioration in shareholder value. The equity ratio is relatively stable, providing a moderate level of financial stability.

Cash Flow

The cash flow statement highlights negative free cash flow each year, with a free cash flow of -$408.07 million in 2024, driven by high operating cash outflows. The operating cash flow to net income ratio is unfavorable due to consistent losses, signaling inefficiencies in cash generation relative to expenses. This is typical for a biotech firm still in development phases.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
45.57M	57.88M	36.27M	52.12M	33.05M	57.99M
	Gross Profit
40.40M	47.59M	27.30M	44.55M	26.16M	-92.41M
	EBIT
-541.07M	-534.26M	-515.29M	-458.16M	-267.85M	-136.58M
	EBITDA
-530.80M	-523.98M	-506.31M	-450.59M	-260.96M	-130.27M
	Net Income Common Stockholders
-525.91M	-519.02M	-481.19M	-490.21M	-259.72M	-125.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
296.58M	601.51M	912.22M	1.26B	1.09B	597.37M
	Total Assets
344.36M	1.19B	1.30B	1.52B	1.29B	676.32M
	Total Debt
19.51M	210.20M	115.35M	130.70M	74.02M	39.30M
	Net Debt
-27.58M	21.02M	-111.40M	-392.80M	-49.38M	-120.72M
	Total Liabilities
80.03M	319.06M	250.81M	284.53M	254.22M	149.25M
	Stockholders Equity
264.34M	871.96M	1.05B	1.24B	1.04B	527.07M
Cash Flow		Free Cash Flow
-381.15M	-354.66M	-408.07M	-391.68M	-237.79M	-53.50M
	Operating Cash Flow
-377.15M	-348.88M	-394.09M	-333.29M	-225.03M	-49.91M
	Investing Cash Flow
213.99M	125.57M	-31.35M	160.31M	-550.78M	-214.49M
	Financing Cash Flow
125.75M	185.75M	130.32M	582.96M	736.69M	371.78M

Intellia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Positive. The current price of 9.6 is above the 20-day moving average (MA) of 8.46, above the 50-day MA of 8.18, and below the 200-day MA of 12.47, indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 62.26 is Neutral, neither overbought nor oversold. The STOCH value of 76.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTLA.

Intellia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NRIX	60 Neutral	$868.32M	―	-64.16%	―	-30.25%	-5.92%
Sector *	54 Neutral	$5.25B	3.27	-44.35%	6.27%	16.79%	-0.10%
XNCR	52 Neutral	$591.43M	―	-33.48%	―	-25.88%	-29.16%
ARVN	51 Neutral	$545.25M	―	-35.41%	―	-39.92%	7.38%
NTLA	50 Neutral	$928.11M	―	-57.92%	―	-13.37%	2.57%
VIR	50 Neutral	$705.01M	―	-44.59%	―	-73.79%	-5.24%
RCKT	40 Underperform	$304.90M	―	-60.45%	―	―	6.99%

Intellia Therapeutics Corporate Events

Intellia Therapeutics Announces Positive Phase 1 Trial Data

On June 15, 2025, Intellia Therapeutics announced positive three-year data from the Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress. The trial showed a 98% mean reduction in monthly HAE attack rates with a single dose, and the treatment was well-tolerated with no serious adverse events. The ongoing global Phase 3 HAELO trial has completed screening ahead of schedule, and Intellia plans to present further data in 2025, with a U.S. launch expected in 2027, pending FDA approval.

The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Therapeutics Holds Annual Stockholders’ Meeting

On June 11, 2025, Intellia Therapeutics held its annual stockholders’ meeting, where several key decisions were made. The stockholders approved the 2025 Equity Incentive Plan, elected three directors for a three-year term, ratified Deloitte & Touche LLP as the independent auditor for 2025, and decided on an annual frequency for advisory votes on executive compensation. These decisions are expected to impact the company’s governance and operational strategies.

The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Therapeutics Updates on Phase 3 Study Progress

On May 28, 2025, Intellia Therapeutics provided a business update on its Phase 3 studies. The HAELO study for NTLA-2002 in hereditary angioedema and the MAGNITUDE-2 study for nex-z in ATTRv-PN are progressing well, with anticipated U.S. commercial launches in 2027 and 2029, respectively. The MAGNITUDE study for ATTR-CM is also on track, with over 200 patients dosed and expected enrollment completion by early 2027. Adverse events reported in the MAGNITUDE study have been consistent with earlier phases, with one recent case of asymptomatic liver transaminase elevations resolving without intervention.

The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Therapeutics Reports Positive Phase 1 Trial Results

On May 18, 2025, Intellia Therapeutics announced positive two-year follow-up data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). The study showed a significant reduction in serum TTR levels and clinically meaningful improvements in neuropathic impairment measures, with no serious adverse events, indicating potential for nex-z as a one-time treatment. The results were presented at the Peripheral Nerve Society Annual Meeting, highlighting the drug’s potential to improve outcomes for patients who previously showed disease progression on patisiran.

The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.